Leiomyoma
Return to Library
Study data from State University of New York update knowledge of leiomyoma
2009 JUL 13 - (NewsRx.com) -- "Bilateral uterine artery embolization has become an accepted therapeutic modality in the management of patients with symptomatic uterine leiomyomata. Complications of bilateral uterine artery embolization, including rare cases of malignancies, have been reported following this procedure," investigators in the United States report. "We present a 46-year-old woman, gravida 3, para 1, who was treated with bilateral uterine artery embolization for symptomatic uterine leiomyomata following pelvic sonography and magnetic resonance imaging, which depicted bilateral normal adnexa. Nine months after the procedure she was diagnosed with stage III ovarian carcinoma," wrote A. Wagreich and colleagues, State University of New York. The researchers concluded: "Patients undergoing bilateral uterine artery embolization should be informed of the possibility of preexisting or potential subsequent development of ovarian carcinoma, reflecting the lack of ail effective screening method for this disease. (J Reprod Med 2009;54:325-326)." Wagreich and colleagues published their study in the Journal of Reproductive Medicine (Advanced Ovarian Carcinoma Following Bilateral Uterine Artery Embolization A Case Report. Journal of Reproductive Medicine, 2009;54(5):325-326). For additional information, contact O. Abulafia, Suny Downstate Med Center, Dept. of Obstetrics & Gynecology, Division Gynecology Oncology, Brooklyn, NY 11203, USA. The publisher of the Journal of Reproductive Medicine can be contacted at: Science Printers & Publ Inc., PO Drawer 12425 8342 Olive Blvd., St. Louis, MO 63132, USA. Keywords: United States, Brooklyn, Angiology, Embolization, Gynecology, Leiomyoma, Leiomyomata, Oncology, Ovarian Cancer, Ovarian Carcinoma, Therapy, Treatment, Uterine Artery, Women's Health, State University of New York. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
